More mergers expected in Pharma industry, says report
Pfizer's merger with Wyeth will bring significant change to the pharmaceutical industry and may result in more large deals before the end of the year, according to a report from UK publisher Urch Publishing.
Pfizer's merger with Wyeth will bring significant change to the pharmaceutical industry and may result in more large deals before the end of the year, according to a report from UK publisher Urch Publishing.
The 111-page report, "Mergers and Acquisitions in the Pharmaceuticals Sector, 2009 - Critical success factors for competing in a consolidating market", says 2009 is set to redefine the structure and dynamics of the pharmaceutical industry in a way not seen since 2000.
It is likely that the "mega-M&A" wave started by the three deals agreed in the first quarter of 2009 (Pfizer/Wyeth, Roche/Genentech, Merck & Co/Schering-Plough) is not yet finished, with possibly three more on the horizon.
"The two most likely deals appear to be the acquisitions of Bristol-Myers Squibb and Bayer," says report author Steve Seget. "Currently the best placed acquisitors appear to be Sanofi-Aventis and Novartis, but we should not rule out Johnson & Johnson or GlaxoSmithKline, if its acquisition of Allergan does not come to fruition."
The companies under most pressure to make acquisitions are Eli Lilly, GlaxoSmithKline and Takeda.